LENZ Therapeutics Inc.

LENZ | NASDAQ

Price Alert Chart Builder DCF Calculator

$4.08

+$0.01 (+0.25%)

At close: Sep 21, 2026, 4:00 PM ET

$4.08

$0 (0.00%)

After-hours: Sep 21, 2026, 7:30 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Overview Market Cap Employees

Company Profile

LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.

Key Executives

Name	Position
Evert Schimmelpennink	President, Chief Executive Officer, Secretary & Director
Daniel R. Chevallard	Chief Financial Officer
David Choromanski	Vice President of Marketing
Domenick Porfidia	Vice President of Sales
James W. McCollum	Co-Founder & Director
Kris Gambelin	Senior Vice President of Regulatory & Clincal Operations
Marc G. Odrich	Chief Medical Officer
Melissa Rosness	Senior Vice President of Manufacturing Operations
Shawn Olsson	Chief Commercial Officer

Latest SEC Filings

Date	Type	Title
Aug 11, 2026	10-Q	Quarterly Report
Aug 11, 2026	8-K	Current Report
Jul 02, 2026	8-K	Current Report
Jun 26, 2026	SC 13G	Statement of acquisition of beneficial ownership b...
Jun 15, 2026	4	Filing
Jun 15, 2026	4	Filing
Jun 15, 2026	4	Filing
Jun 15, 2026	4	Filing
Jun 15, 2026	4	Filing
Jun 15, 2026	4	Filing

View All SEC Filings ➞

LENZ Therapeutics Inc.

Country	United States
IPO Date	Jun 24, 2021
Industry	Biotechnology
Sector	Healthcare
Employees	152
CEO	Evert Schimmelpennink

Contact Details

201 Lomas Santa Fe Drive Solana Beach, California 92075 United States

https://www.lenz-tx.com

(858) 925-7000

Stock Details

Ticker Symbol	LENZ
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001815776
CUSIP Number	52635N103
ISIN Number	US52635N1037
SIC Code	2836